Select Page
Provide enabling innovation
in healthcare
Provide enabling innovation
in healthcare

aeChem Sàrl is a Swiss start-up company relentlessly focused on providing a spectrum of platforms for modern personalized medicines based on our synthetic molecules.

Engineering

Our heart is made of carefully developed skills in chemistry, bio-chemistry and IVD assay development. We can build for you the best protein, molecules and surface ligation solution based on your needs.

Our tailored products

L-KER

Our L-KER chemical platform is designed to provide a controlled system to produce drug conjugates based on antibodies or high-end bioconjugates.

Antibody-targeted therapy against cancers is a fast-growing market, fueled by extensive research and development. Despite these advances some patients still succumb due to suboptimal action of the drug. A variation is antibody drug conjugates (ADCs) where a toxic payload is coupled to the antibody to enhance its effect. However, this conjugate is technically difficult to obtain without sacrificing the advantages of the antibody. L-KER is designed to provide a controlled system to produce drug conjugates based on antibodies.

SensOSE

The SensOSE membrane is designed for the next generation of rapid test product focused on oligonucleotides and peptides.

Rapid tests (RT) allow fast and cheap in-vitro diagnostic of diseases using biochemical assay on cellulose membrane using physiological biomolecules as markers. However, to cure efficiently patients by limiting sequels, early diagnostic of diseases is required. Here molecular diagnostic tools, where DNA is tested, are needed and are not possible with current RT. SensOSE membrane is designed to open unmet potential for next generation RT where DNA is tested.

fluXell

The fluXell cartridge will tackle the expensive, time-consuming and limiting step of blood processing and cells selection for a large spectrum of applications.

Modern therapies and diagnostic procedures require high quality and specificity during the preparation of samples from patients. FluXell, our in-development cartridge, will tackle the complex, expensive and time-consuming step of patient blood processing, and is designed to be embedded into any laboratory workflow or automated units.

Our tailored products

L-KER

Our L-KER chemical platform is designed to provide a controlled system to produce drug conjugates based on antibodies or high-end bioconjugates.

Antibody-targeted therapy against cancers is a fast-growing market, fueled by extensive research and development. Despite these advances some patients still succumb due to suboptimal action of the drug. A variation is antibody drug conjugates (ADCs) where a toxic payload is coupled to the antibody to enhance its effect. However, this conjugate is technically difficult to obtain without sacrificing the advantages of the antibody. L-KER is designed to provide a controlled system to produce drug conjugates based on antibodies.

SensOSE

The SensOSE membrane is designed for the next generation of rapid test product focused on oligonucleotides and peptides.

Rapid tests (RT) allow fast and cheap in-vitro diagnostic of diseases using biochemical assay on cellulose membrane using physiological biomolecules as markers. However, to cure efficiently patients by limiting sequels, early diagnostic of diseases is required. Here molecular diagnostic tools, where DNA is tested, are needed and are not possible with current RT. SensOSE membrane is designed to open unmet potential for next generation RT where DNA is tested.

fluXell

The fluXell cartridge will tackle the expensive, time-consuming and limiting step of blood processing and cells selection for a large spectrum of applications.

Modern therapies and diagnostic procedures require high quality and  specificity during  the preparation of samples from patients. FluXell, our in-development cartridge, will tackle the complex, expensive and time-consuming step of patient blood processing, and is designed to be embedded into any laboratory workflow or automated units.

 

Contact us for more information!

If you prefer, you may contact us by e-mail at info@aechem.ch or via our linkedIn accounts.

8 + 7 =

aeChem Team

Established in Switzerland at BioArk Monthey innovation park, aeChem is a company committed to provide enabling innovative technologies and engineering solutions to Personal Medicines market. At the heart of aeChem sits technologies and skills carefully developed over 10 years at the interface of life technologies, in-vitro diagnostic and chemistry by Enrico CONDEMI and Denis PRIM.

Enrico Condemi

Co Founder

Mobile: +41 78 644 64 70
e-mail: enrico.condemi@aechem.ch

Denis Prim

Co Founder

Mobile: +41 79 612 83 47
e-mail: denis.prim@aechem.ch

aeChem SàrL
BioArk
Route de l'Ile-au-Bois 1A
1870 Monthey
Switzerland

aeChem Sàrl is coached by The Ark Foundation and located at BioArk Monthey
Valais, Switzerland